As India fights the second wave of COVID infections, the government has introduced an anti-COVID medication that has been found to help speed up recovery and minimise oxygen dependency.
The drug, known as 2-deoxy-D-glucose (2-DG), was developed in partnership with Hyderabad-based Dr Reddy’s Laboratories by the Institute of Nuclear Medicine and Allied Sciences, which is a lab under the Defence Research and Development Organisation (DRDO). The Drugs Controller General of India (DCGI) approved the drug’s emergency use as an adjunct or supplement therapy in moderate to serious COVID patients earlier in the month of May.
Here are 5 things you need to know about the 2-DG drug:
If you enjoyed reading this, we suggest you also read: